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Abstract
Background: Longstanding evidence implicates an inadequate diet as a key factor in the onset and progression of 
prostate cancer. The purpose herein was to discover, validate and characterize functional biomarkers of dietary 
supplementation capable of suppressing the course of prostate cancer in vivo.
Methods: The Lady transgenic mouse model that spontaneously develops prostate cancer received a diet 
supplemented with a micronutrient cocktail of vitamin E, selenium and lycopene ad libitum. A proteomic analysis was 
conducted to screen for serum biomarkers of this dietary supplementation. Candidate peptides were validated and 
identified by sequencing and analyzed for their presence within the prostates of all mice by immunohistochemistry.
Results: Dietary supplementation with the combined micronutrients significantly induced the expression of the 
megakaryocyte-specific inhibitor of angiogenesis, platelet factor-4 (P = 0.0025). This observation was made 
predominantly in mice lacking tumors and any manifestations associated with progressive disease beyond 37 weeks of 
life, at which time no survivors remained in the control group (P < 0.0001). While prostates of mice receiving standard 
chow were enlarged and burdened with poorly differentiated carcinoma, those of mice on the supplemented diet 
appeared normal. Immunohistochemical analysis revealed marked amplifications of both platelet binding and platelet 
factor-4 within the blood vessels of prostates from mice receiving micronutrients only.
Conclusion: We present unprecedented data whereby these combined micronutrients effectively promotes tumor 
dormancy in early prostate cancer, following initiation mutations that may drive the angiogenesis-dependent response 
of the tumor, by inducing platelet factor-4 expression and concentrating it at the tumor endothelium through 
enhanced platelet binding.
Background
Prostate cancer (PCa) remains the second leading cause
of cancer related deaths in North American men,
although the rate has been declining in part from the use
of statin drugs for unrelated medical conditions [1]. In
spite of recent reports that place into question the benefit
of dietary supplementation with respect to overall sur-
vival following diagnosis of PCa, preclinical studies con-
tinue to reveal significant benefits using micronutrient
cocktails as preventative regimens in spontaneous mouse
models of PCa [2].
Among the many micronutrients tested for their anti-
cancer properties, vitamin E, a major intracellular antiox-
idant, remains one of the most studied [3-8]. We have
previously determined that the effect of vitamin E in PCa
is mediated, at least in part, by the induction of cell cycle
arrest through the modulation of the cdk inhibitor,
p27Kip1 [7]. Selenium has been implicated in playing a
chemopreventive role in various cancers, including PCa
[8,9]. We have shown that selenium also induces cell cycle
arrest in vitro but only in the presence of a functional
androgen receptor [10]. Finally, the carotenoid, lycopene,
has shown considerable clinical benefits in both diabetic
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and PCa patients, particularly when combined with other
tomato nutrients [11]. Lycopene has also been proven to
act synergistically as a chemopreventive agent when com-
bined with ketosamines in vitro [12]. Aside from the well
reported intracellular mechanisms of these micronutri-
ents as single agents, no studies have surfaced to suggest
how the host responds to the combination of these
micronutrients that may suppress tumor growth. The
rationale herein to use all three in combination comes
from previous studies conducted in our laboratory [2,13].
We have reported synergistic properties between vitamin
E and selenium that induce growth arrest of LNCaP cells
in vitro over either antioxidant alone [14]. As well, lyco-
pene as a single agent has similarly been shown to be
effective  in vitro, yet this response is not necessarily
reflected in vivo (unpublished data). Thus, we tested all
three in combination for their ability to induce the pro-
duction of functional biomarkers that could potentially
be responsible for the delayed progression of prostate
cancer observed in the Lady mouse model of PCa [13].
We present here a proteomic approach that has deci-
phered an anti-angiogenesis response in vivo by the com-
bined administration of vitamin E, selenium and lycopene
(E/S/L) in a spontaneous mouse model of adenocarci-
noma of the prostate. We have found that these micronu-
trients can induce the expression of PF-4, a
megakaryocyte-specific protein that is an endogenous
inhibitor of angiogenesis. We propose the mechanism
that the subsequent upregulation of PF-4 in platelets
upon terminal differentiation of the megakaryocyte
allows for the delivery of the elevated protein to the
tumor, thereby suppressing tumor-dependant angiogene-
sis and promoting a dormant phenotype in the Lady
mouse.
Methods
Mice and dietary conditions
Female  Lady  transgenic mice (12T-10) were obtained
from Dr. Robert J. Matusik (Vanderbilt Prostate Center,
Vanderbilt University Medical Center, Nashville, TN). All
animals were housed and maintained according to insti-
tutional guidelines set forth by Sunnybrook Health Sci-
ences Centre, Toronto, Canada and in accordance with
the Canadian Council on Animal Care. Animal research
reported in the manuscript has been performed with the
approval of the Sunnybrook Research Ethics Board and
conducted as per institutional guidelines set forth by
Sunnybrook Health Sciences Centre, Toronto, Canada
and in accordance with the Canadian Council on Animal
Care. Animals were fed either standard chow or a chow
supplemented with the antioxidants, vitamin E (α-
tocopherol succinate) (800IU), selenium (seleno-DL
methionine) (200 μg) and lycopene (50 mg) (Purina Mills
Test Diet, Richmond, Indiana). The latter diet is abbrevi-
ated henceforth, E/S/L. All animals were maintained on
each diet for a period of 42 weeks.
Serum processing and Surface-enhanced Laser Desorption 
Ionization - Time-of-Flight Mass Spectrometry (SELDI-ToF 
MS)
All mice were anaesthetized by inhalation (Isoflurane-4%
induction/2% maintenance) prior to whole blood collec-
tion via cardiac puncture using a 1cc syringe fitted with a
26 gauge/0.5 cm needle. The blood was quickly dispensed
into 1.5 mL microcentrifuge tubes and allowed to clot on
ice. The clotted blood was then centrifuged at 14,000 g for
5 minutes followed by collection of the top phase (serum)
and storage at -80°C until processing time. Serum (20 μL)
was fractionated by anion-exchange chromatography
adopted from the Expression Difference Mapping (EDM)
Serum Fractionation protocol (Ciphergen, Fremont, CA)
in a 96-well format filter plate.
Expression difference mapping (EDM) on ProteinChip
arrays was carried out using carboxymethyl ProteinChip
arrays (CM10 ProteinChip arrays; Ciphergen, Fremont,
CA) and readings were performed using the Protein Biol-
ogy System IIC (PBSIIC) processed with the ProteinChip
Software Biomarker Edition®, Version 3.2.0 (Ciphergen,
Fremont, CA). After baseline subtraction, spectra were
normalized by means of a total ion current. Peak detec-
tion was performed by using Biomarker Wizard software
(Ciphergen, Fremont, CA) using a minimum peak detec-
tion criteria of a signal-to-noise ratio greater than 3.
Gel purification and sequencing of candidate peptides
A 20 μL sample of the peptide-containing fraction was
resolved on NuPAGE® Novex Bis-Tris Gels polyacrylam-
ide gels (Invitrogen) and a SeeBlue® Plus2 Pre-Stained
Standard (Invitrogen) was loaded into a single well as ref-
erence markers. SilverQuest™ Silver Staining Kit (Invitro-
gen) was used according to manufacture's protocol to
stain peptides after resolving. Extraction of peptides with
apparent molecular weights corresponding to those
found to be significantly different between the two
groups of mice (Table 1) were excised from the gels using
a fine (1 mm) pasture pipet. The protein-containing band
was in-gel digested with try sin and processed for
sequencing according to previously published procedures
[15] and subjected to LC-MS/MS analysis (Agilent 1100
HPLC-chip and 6340 ion trap MSD system, Agilent Tech-
nologies). Raw MS/MS results were searched against
NCBInr restricted to mammals' subset database, using
Spectrum Mill MS Proteomics Workbench (Agilent
Technologies). Proteins with two or more peptides identi-
fied from MS/MS search were reported.Cervi et al. BMC Cancer 2010, 10:258
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Tissue sampling and immunohistochemistry
All animals were examined for gross abnormalities
according to previously described methods [2,13]. Pros-
tate glands were fixed in 10% (v/v) buffered formalin, par-
affin-embedded and cut into 5 μm sections mounted
onto glass slides. The sections were deparaffinized with
xylene, rehydrated and boiled for 10 min in citrate buffer
(pH 7.0). They were then blocked with 0.3% hydrogen
peroxide in methanol followed by normal serum and then
incubated overnight at 4°C with the primary antibody
against mouse PF-4 (anti-PF-4, mouse monoclonal anti-
body (Santa-Cruz Biotechnology) diluted 1:70 in PBS) or
against anti-CD41 (anti-CD41, rat monoclonal antibody
(Abcam) diluted 1:50 in PBS). Slides were then reacted
with biotin-labeled anti-mouse IgG/anti-rat IgG and
incubated with preformed avidin-biotin peroxidase com-
plex (Vector Laboratories). Sections were counterstained
with hematoxylin, dehydrated, and mounted. The expres-
sions of both PF-4 and CD41 were scored based on the
intensity of staining (absence of staining, weak or strong)
by two independent investigators.
Results
Reduced tumor burden and extended survival are 
observed for mice receiving a supplemented diet of E/S/L
Lady transgenic mice were placed on a standard diet or a
diet supplemented with vitamin E (800 IU), selenium
(200 μg) and lycopene (50 mg) for a period of 37 weeks
from weaning. We have previously shown that by this
time, 90% of animals on a standard diet develop prostate
cancer, but that 85% of animals administered the micro-
nutrients have completely normal, benign prostates. Sim-
ilar gross and histological differences between the two
groups were observed here as with our previous study ,
with an overall significant survival benefit achieved for
mice consuming the supplemented diet [2,13].
Serum proteomic analysis reveals an upregulation of PF-4 
in Lady transgenic mice receiving E/S/L-supplemented 
diets
Serum obtained at the end of the study period from Lady
mice receiving a standard diet alone or an E/S/L-supple-
mented diet were subjected to a standard biomarker dis-
covery protocol according to Materials and Methods. Ten
peptides in total were observed to be significantly dereg-
ulated with respect to their serum concentrations (Table
1, p < 0.01). Molecular weights of these peptides ranged
between 2297 and 8963 Da with the majority of proteins
exhibiting alkaline properties (high isoelectric point (pI))
based on their binding properties to the chromatographic
resins used in their discovery. Following purification of
the fractionated specimens outlined in Table 1 for
sequencing purposes, the resolving power of gel electro-
phoresis limited the number of candidates for sequencing
to a single, prominent band with an apparent molecular
weight approximating 9000 Da (data not shown); corre-
sponding to the 8963 Da candidate biomarker discovered
by SELDI-ToF (Table 1). The expression profiles obtained
Table 1: Candidate serum biomarkers of E/S/L-supplementation.
Average Peak Intensity
Fraction (pH) Peak Mass (Da) P Standard Diet Supplemented 
Diet
9.0 4479.11 0.0019 0.424 0.624
9.0 7489.44 0.0041 0.379 0.224
7.0 6267.37 0.0065 2.105 3.963
7.0 6483.69 0.0012 0.176 0.481
7.0 6824.78 0.0065 2.805 5.143
7.0* 8963.14 0.0025 0.239 0.531
4.0 2297.16 0.0065 2.566 1.182
4.0 2927.47 0.0065 1.090 0.571
4.0 5586.30 0.0019 1.163 0.659
3.0 2902.33 0.0055 0.585 0.240
*PF-4
Serum obtained at the end of the study period from Lady mice receiving a standard diet alone or an E/S/L-supplemented diet were subjected to 
a standard biomarker discovery protocol according to Materials and Methods. Ten peptides in total were observed to be significantly 
deregulated with respect to their serum concentrations (Table 1, p < 0.01). Molecular weights of these peptides ranged between 2297 and 8963 
Da with the majority of proteins exhibiting alkaline properties (high isoelectric point (pI)) based on their binding properties to the 
chromatographic resins used in their discovery.Cervi et al. BMC Cancer 2010, 10:258
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for this candidate biomarker during the initial discovery
phase revealed it to be significantly upregulated in the
majority of Lady mice receiving a E/S/L-supplemented
diet (Fig 1, p = 0.0025). Analysis by MS/MS of the 8963
Da peptide showed a high confidence match with murine
chemokine (C-X-C motif) ligand 4 (CXCL4), henceforth
referred to here as, PF-4 (Fig 2).
Amplified intravascular PF-4 and platelet binding in 
prostates of Lady mice administered E/S/L-supplemented 
diets
To ascertain the proteomic analysis and validation of ele-
vated PF-4 in Lady  mice receiving an E/S/L-supple-
mented diet, prostate tissues were processed and
immunostained for PF-4 and α2β-integrin (CD41), the lat-
ter being a surface marker of platelets, which are the bio-
logical vehicles of PF-4 in vivo (see discussion).
Histopathology of prostates was first assessed by H&E for
all animals in both groups. While prostates from mice on
a standard diet were grossly enlarged and burdened with
poorly differentiated carcinoma (74%), those from mice
receiving an E/S/L-supplemented diet were normal, both
grossly and histologically [2,13]. A representative field is
viewed in Fig 3; Panel A. Analysis of PF-4 staining
between the two groups revealed intense staining of the
protein within the vasculature of the prostate in mice
receiving an E/S/L-supplemented diet, but not within the
lymphatic ducts (7 out of 8 or 88%). However, along with
a complete loss of tissue integrity no discernable staining
for PF-4 was observed in the prostates of control mice (1
out of 7 had a very weak staining or 14%) (Fig 3; Panel B-
20X magnification, Panel C-40X). Finally, given the nega-
tive staining for PF-4 in the prostate epithelium and con-
nective tissues and the fact that this protein has solely
been shown to be megakaryocyte-specific, we sought to
confirm its elevated presence in the vasculature of the
prostate to be attributed to the increased binding capac-
ity of circulating platelets. As depicted in Fig 3; Panel D,
the intensity differences in CD41 staining; i.e., platelet
binding, between the two groups are akin to those
observed for PF-4. The vast majority of mice receiving a
E/S/L-supplemented diet therefore exhibited a greater
number of PF-4-containing platelets bound to the blood
vessels of the prostate (5 out of 6 or 83%) versus none for
those in the control group (0 out of 6).
Discussion
The micronutrients, vitamin E, selenium and lycopene
are known to provide cells with an incredibly efficient
free-radical scavenging system, therefore substantially
reducing cancer-promoting DNA damage. While the lit-
erature evidence and current understanding of each sup-
plement strongly supports this view, we report an
unprecedented finding here that the combination of these
three supplements together, but not individually, is also
antiangiogenic by virtue of its ability to induce the
expression of a megakaryocyte-specific, endogenous
inhibitor of angiogenesis, PF-4. Furthermore, E/S/L has
the ability to promote platelet binding to an activated
endothelium and therefore concentrate this inhibitor at
susceptible sites; i.e., tumor-adjacent vasculature.
The initial goal of this study was to conduct a full serum
proteomic analysis to identify and characterize functional
biomarkers of antioxidant supplementation likely to have
an impact on the course of prostate cancer in a spontane-
ous PCa mouse model. We have previously reported an
extended survival benefit in the Lady transgenic mouse
supplemented with an E/S/L cocktail and therefore
wanted to further investigate the molecular mechanisms
in vivo governed by their synergistic properties that could
ultimately be capable of maintaining the extrinsically
mutated prostate epithelium in check [2,13]. Individually,
these antioxidants imparted no benefits compared to
those observed in the combination group; i.e., reduced
Figure 1 Validation and identification of serum PF-4. Serum was 
harvested from Lady mice receiving either a standard diet (black) (n = 
10) or a E/S/L-supplemented diet (red) (n = 10) at the study endpoint 
(37 weeks). A standard comparison was made using the SELDI-ToF bio-
marker discovery method. A spectral readout from SELDI-ToF MS be-
tween the two groups is presented here in gel-view format with a 
specific emphasis on the banding pattern related to the peptide can-
didate with an apparent molecular weight of 8960 Da.
8500              9000  9500
8500               9500Cervi et al. BMC Cancer 2010, 10:258
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tumor burden and extended survival [2]. Serum profiling
was therefore restricted to compare Lady transgenic mice
receiving a standard diet with those receiving E/S/L-sup-
plementation, as the latter group alone clearly exhibited
the benefits. It is important to note that while we have
successfully identified PF-4 as a biomarker of dietary
response by differential expression, validation and isola-
tion, univariate data analysis of the complete proteome
validated an additional 9, differentially expressed pep-
tides (p < 0.01) between these two groups of mice (Table
1). These peptides ranged in molecular weights of 2200-
7400 Da. Their identifications, however, have been ham-
pered largely by inadequate resolving power of gel elec-
trophoresis. It is conceivable, therefore, that the
expression patterns of other proteins, in addition to PF-4,
may be playing as intricate a role in controlling the pro-
gression of early-stage prostate cancer.
Having identified PF-4 as a dietary biomarker of E/S/L-
supplementation implicates a very intricate biologic path-
way that alters the hemostatic balance in vivo to subse-
quently suppress the activated endothelium in the
cancerous prostate. This response likely lies initially at
the level of the megakaryocyte since it is the sole source
for PF-4 that is currently known in vivo [16-18]. In fact,
our findings here indicate that the prostate gland stained
negatively for PF-4 and that the intense staining pattern
was restricted to the intravascular regions of the gland,
but only in mice receiving the E/S/L cocktail. In light of a
recent report suggesting that upregulation of PF-4 may
play a crucial role in the early stages of several cancers
[19], we propose here that upregulation of this peptide in
our study was crucial in preventing angiogenesis at the
tumor site in early prostate cancer. More importantly, this
r esponse could ha ve only been initially media t ed via a
biologic modulation of the megakaryocyte located at a
distant site from the tumor itself (bone marrow and
spleen). Platelets, being the endpoint of megakaryocyte
differentiation, now carrying an increased load of PF-4,
would later bind to the activated endothelium of the can-
cerous prostate where it would subsequently suppress the
angiogenic drive induced by the developing tumor fol-
lowing its angiogenic switch. The existence of such a
switch has been long proposed and recently proven in
tumor biology [20,21]. Overall, our findings of elevated
PF-4 and improved shuttling of the protein suggest that
in vivo, such properties can preclude the angiogenic drive
of most tumors, particularly following initiation muta-
tions governing the angiogenic switch. In doing so, the
tumor can be kept in check by the host during its earliest
stages and prevented from further localized invasion and
metastatic spread, albeit in the presence of E/S/L. This is
the preclinical interpretation that we propose in light of
our findings herein and the current literature pertaining
to tumor angiogenesis.
We have considered an additional mechanism to our
observed benefit of E/S/L-supplementation in the Lady
mouse. Platelet activation and binding, which are intrin-
sic functions of platelets and occur irrespective of dietary
supplementation, should have occurred in both groups of
animals, which indeed was the case. However, mice
receiving the cocktail exhibited a greater degree of plate-
let binding capacity (￿α2β-integrin) to the activated
endothelium of the cancerous prostate. Although any
mechanism suggested at this stage would be purely spec-
ulative we have considered that differences in platelet
numbers alone between the two groups (reduced in
tumor-bearing animals versus elevated in treated ani-
mals) may have perhaps contributed to such apparent dif-
ferences. However, for E/S/L-supplementation to
promote platelet production it would necessitate having
to increase the number of its megakaryocyte precursors
in the hematopoietic compartments of Lady mice. Analy-
sis of spleens obtained from both groups indicated no
such differences in the current study (data not shown).
Furthermore, there has been no indication in our studies
that changes in platelet numbers results from progressive
disease or to dietary supplementation (unpublished
results).
Figure 2 Peptide purification and sequencing. Intensity differences of the bands are reflective of the serum concentrations of the peptide in each 
mouse. This peptide was later purified and sequenced according to Materials and Methods and identified as murine CXCL4 (PF-4). Contaminating 
peptides from serum processing and handling are shown as well in the sequencing readout.
PF-4
MW Score Intensity Peptide IDCervi et al. BMC Cancer 2010, 10:258
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Conclusions
The findings we are reporting here outline a completely
novel biologic mechanism involving the use of well docu-
mented micronutrients as a preventative therapy for the
progression of prostate cancer. We have provided unprec-
edented data to prove that this combined supplementa-
tion is a natural antiangiogenic therapy by virtue of its
ability to upregulate an endogenous inhibitor of angio-
genesis, PF-4 (p = 0.0025). While a family of micronutri-
ents, referred to in the literature as neutriceuticals, have
shown to be antiangiogenic, these studies have supported
such a role through altered signalling pathways related to
oxidative stress in endothelial cells [22,23]. We, however,
have serendipitously discovered this particular antioxi-
dant cocktail to be antiangiogenic by an indirect physio-
logical pathway involving the platelet precursor, the
megakaryocyte. Implicit in this finding is the potential
clinical benefit that can be achieved through dietary sup-
plementation, particularly during the earliest stages of
cancer development and at a time when they become
angiogenesis-dependant.
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